Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Atossa Genetics Inc. (ATOS : NSDQ)

• Company Description    Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting research on the treatment of pre-cancerous cells by using its FDA-cleared microcatheters to deliver, directly into the milk ducts, anti-cancer drugs that can be used to treat the pre-cancerous lesions. Atossa Genetics Inc. is headquartered in Seattle, WA. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $0.89 Daily Weekly Monthly 20 Day Moving Average: 1,449,954 shares Shares Outstanding: 129.17 (millions) Market Capitalization: $114.69 (millions) Beta: 0.90 52 Week High: $1.66 52 Week Low: $0.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.91% -0.94% 12 Week 42.50% 19.86% Year To Date -5.95% -11.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10202 5th Avenue NE Suite 200 - SEATTLE,WA 98125 USA ph: 206-588-0256 fax: 206-430-1288 michael.parks@atossainc.com http://www.atossagenetics.com

• General Corporate Information    Officers Steven C. Quay - Chief Executive Officer;Chairman; President Heather Rees - Chief Financial Officer Richard I. Steinhart - Director Shu-Chih Chen - Director Jonathan Finn - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 04962H506 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 129.17 Most Recent Split Date: 4.00 (0.08:1) Beta: 0.90 Market Capitalization: $114.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.24 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.76 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -33.90 12/31/24 - -30.59 ROA 06/30/25 - - 03/31/25 - -31.53 12/31/24 - -28.59 Current Ratio 06/30/25 - - 03/31/25 - 12.67 12/31/24 - 14.99 Quick Ratio 06/30/25 - - 03/31/25 - 12.67 12/31/24 - 14.99 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.51 12/31/24 - 0.57 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©